ADDvise signs Letter of Intent to acquire Innovative Endoscopy Components, LLC.

15-06-2023   Regulatory press release

ADDvise has signed a Letter of Intent with the shareholders of Innovative Endoscopy Components, LLC. (”IEC”) regarding an acquisition of all shares in IEC.

IEC is an international provider of endoscopy equipment and endoscopy spare parts based in Fort Lauderdale, Florida, USA. The company manufactures, supplies and repairs OEM and aftermarket parts to the endoscopy industry with customers in over 100 countries.


The company’s revenue for the last twelve months as of May 31, 2023 amounted to USD 9.4 million with an EBITDA of USD 1.7 million, corresponding to an EBITDA margin of 18.4 percent.


The purchase price for IEC amounts to an initial payment of USD 8.25 million, and two potential earn-outs of USD 1.75 million in total.


The acquisition will be financed with own funds and existing credit facilities. ADDvise assesses that the acquisition will have a positive impact on ADDvise earnings per share for the financial year 2023.


The acquisition is subject to a due diligence and that the parties agree to enter into a share purchase agreement. The acquisition is expected to be completed during the second half of 2023.

The previously communicated Letter of Intents to acquire Reina and Diabetic Supplies are expected to be completed during the third quarter 2023.

For further information, please contact:

Rikard Akhtarzand, CEO
+46 765-25 90 71
rikard.akhtarzand@addvisegroup.se

Important information

This information is by ADDvise Group AB required to disclose under the EU Market Abuse Regulation. The information was submitted for publication on June 15, 2023, at 16:20 CEST.

About ADDvise Group

ADDvise Group AB (publ) is a leading supplier of equipment to healthcare and research facilities. The Group consists of two business areas, Lab and Healthcare. Sales are global. The Group has a clear acquisition strategy with the aim of raising shareholder value and expanding the business - both geographically and product-wise. ADDvise Group's shares are listed on Nasdaq First North Premier Growth Market and Mangold Fondkommission AB, +46 8 503 015 50, CA@mangold.se,is the Company's Certified Adviser. Additional information is available at www.addvisegroup.com.

 

 

Latest press releases

Interim report 2025, January 1–March 31

Regulatory

In the first quarter of 2025, net revenue increased organically with continued good profitability, which shows stable demand in medical technology and laboratory solutions. Cash flow from operating activities was strong, driven by improved working capital while EBITA, the company’s new main profit measure, decreased compared to the same quarter last year. Through increased operational…

Invitation to presentation of interim report January 1 – March 31, 2025

Non-regulatory

ADDvise Group publishes its interim report January 1 – March 31, 2025 on Friday, May 9, 2025 at 7.45 am (CET). Media, investors and analysts are invited to attend a webcast and teleconference on the same day at 14:00 (CET). CEO, Staffan Torstensson, and Interim CFO, Johan Irwe, will present the report. Webcast If you wish…

Notice to the annual general meeting of ADDvise Group AB (publ)

Regulatory

ADDvise Group AB (publ), reg. no. 556363–2115, hereby convenes the annual general meeting on 12 May 2025 at 10:00 CEST at Grev Turegatan 30 in Stockholm. Entrance and registration start at 09.30 CEST. NOTIFICATION Shareholders wishing to attend the annual general meeting must: i)          be registered in the share register kept by Euroclear Sweden AB on the…

ADDvise raises approximately SEK 457 million in the rights issue

Regulatory

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES (INCLUDING ITS TERRITORIES), AUSTRALIA, CANADA, BELARUS, HONG KONG, JAPAN, NEW ZEALAND AND RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL,…